Gentex VP logs stock awards and share sales

Gentex Corporation vice president of sales Matthew Chiodo reported a mix of stock awards, tax-related share dispositions, and open-market sales of common stock.

Accepted by SEC EDGAR 02/19/2026 - 04:34 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Gentex Corporation vice president of sales Matthew Chiodo reported a mix of stock awards, tax-related share dispositions, and open-market sales of common stock. On February 17, he received a grant of 28,269 performance-based shares, with the number tied to long-term performance incentives and vesting 100% three years from the grant date. That same day, Form 4 data shows tax-withholding dispositions of shares at about $24.89 per share and open-market sales totaling 19,827 shares at about $25.03 per share. On February 19, he received an additional award of 12,047 shares of common stock, bringing his directly held stake to 47,148 shares after the reported transactions.

Insider Trade Summary

Net Seller: 19,827 shares

Net Sell 6 txns

Insider Chiodo Matthew

Role Vice President of Sales

Sold 19,827 shs ($496K)

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	12,047	$0.00	$0.00
Grant/Award	Common Stock	28,269	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	12,564	$24.89	$313K
Exercise Price or Tax Liability	Common Stock	3,187	$24.89	$79K
Sale	Common Stock	15,705	$25.025	$393K
Sale	Common Stock	4,122	$25.025	$103K

Holdings After Transaction: Common Stock — 47,148 shares (Direct)

Footnotes (3)

1. F1. 28,269 shares are performance-based shares where the total number of shares granted were based on long term performance incentives.
2. F2. Shares purchased through the Gentex Corporation Employee Stock Purchase Plan, a Section 423(b) plan
3. F3. These shares vest 100% three years from grant award date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Gentex (GNTX) executive Matthew Chiodo report?

Matthew Chiodo reported stock grants, tax-related share dispositions, and open-market sales of Gentex common stock. The filing shows performance-based awards, shares withheld to cover taxes, and open-market sales executed around $25 per share.

How many Gentex (GNTX) shares did Matthew Chiodo sell in the market?

The Form 4 shows open-market or private sales totaling 19,827 shares of Gentex common stock. These sales occurred on February 17 at an approximate price of $25.025 per share, according to the reported transaction details.

What Gentex (GNTX) stock awards did Matthew Chiodo receive?

Chiodo received 28,269 performance-based shares on February 17 and an additional 12,047 shares on February 19. The 28,269-share award was based on long-term performance incentives and is scheduled to vest 100% three years from the grant date.

Why were some Gentex (GNTX) shares disposed of at $24.89 by Matthew Chiodo?

Shares reported at about $24.89 per share were disposed of to cover tax liabilities or exercise-related obligations. The Form 4 labels these as F-code transactions, meaning payment of tax or exercise costs using delivered securities rather than open-market selling.

How many Gentex (GNTX) shares does Matthew Chiodo hold after these transactions?

After all reported grants, tax-related dispositions, and open-market sales, Chiodo directly holds 47,148 shares of Gentex common stock. This figure reflects his ownership immediately following the February 19 stock award transaction disclosed in the filing.

How do the performance-based Gentex (GNTX) shares for Matthew Chiodo vest?

The filing states that 28,269 performance-based shares vest 100% three years from the grant award date. The total number granted was determined based on long-term performance incentives, linking the award directly to Gentex’s multi-year performance criteria.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chiodo Matthew

(Last) (First) (Middle)

600 N CENTENNIAL

(Street)

ZEELAND MI 49464

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GENTEX CORP [ GNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President of Sales

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A(1)		28,269	A	$0.00	70,679(2)	D
Common Stock	02/17/2026		F		12,564	D	$24.89	58,115	D
Common Stock	02/17/2026		F		3,187	D	$24.89	54,928	D
Common Stock	02/17/2026		S		15,705	D	$25.025	39,223	D
Common Stock	02/17/2026		S		4,122	D	$25.025	35,101	D
Common Stock	02/19/2026		A(3)		12,047	A	$0.00	47,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 28,269 shares are performance-based shares where the total number of shares granted were based on long term performance incentives.

2. Shares purchased through the Gentex Corporation Employee Stock Purchase Plan, a Section 423(b) plan

3. These shares vest 100% three years from grant award date.

Remarks:

	/s/ Scott Ryan for Matthew W. Chiodo by Power of Attorney	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.